

Supplementary 2. Primary and secondary outcome per month – Medical

Month	Pre-implementation N = 2230						Post-implementation N = 2052					
	Total episodes	Total doses	Withheld inappropriately n (%)	95% Confidence Interval	Total withheld n (%)	95% Confidence Interval	Total episodes	Total doses	Withheld inappropriately n (%)	95% Confidence Interval	Total withheld n (%)	95% Confidence Interval
1	29	142	22 (15.5)	10.0-22.5	34 (23.9)	17.2-31.8	25	124	1 (0.8)	0.0-4.4	29 (23.4)	16.3-31.8
2	28	153	24 (15.7)	10.3-22.4	38 (24.8)	18.2-32.5	30	142	7 (4.9)	2.0-9.9	32 (22.5)	16.0-30.3
3	29	181	22 (12.2)	7.8-17.8	41 (22.7)	16.8-29.4	22	118	3 (2.5)	0.5-7.3	23 (19.5)	12.8-27.8
4	30	145	46 (31.7)	24.3-40.0	61 (42.1)	33.9-50.5	29	147	7 (4.8)	1.9-9.6	23 (15.6)	10.2-22.5
5	28	153	30 (19.6)	13.6-26.8	45 (29.4)	22.3-37.3	26	148	7 (4.7)	1.9-9.5	20 (13.5)	8.5-20.1
6	29	146	16 (11.0)	6.4-17.2	29 (19.9)	13.7-27.3	25	135	8 (5.9)	2.6-11.3	16 (11.9)	6.9-18.5
7	28	171	45 (26.3)	19.9-33.6	76 (44.4)	36.9-52.2	25	142	22 (15.5)	10.0-22.5	42 (29.6)	22.2-37.8
8	23	112	10 (8.9)	4.4-15.8	20 (17.9)	11.3-26.2	29	148	3 (2.0)	0.4-5.8	19 (12.8)	7.9-19.3
9	29	158	35 (22.2)	15.9-29.4	57 (36.1)	28.6-44.1	28	142	5 (3.5)	1.2-8.0	23 (16.2)	10.6-23.3
10	28	123	17 (13.8)	8.3-21.2	30 (24.4)	17.1-33.0	23	141	15 (10.6)	6.1-16.9	40 (28.4)	21.1-36.6
11	29	139	19 (13.7)	8.4-20.5	31 (22.3)	15.7-30.1	28	121	3 (2.5)	0.5-7.1	16 (13.2)	7.8-20.6
12	28	117	25 (21.4)	14.3-29.9	39 (33.3)	24.9-42.6	17	96	5 (5.2)	1.7-11.7	20 (20.8)	13.2-30.3
13	28	154	30 (19.5)	13.5-26.6	48 (31.2)	24.0-39.1	21	115	12 (10.4)	5.5-17.5	27 (23.5)	16.1-32.3
14	28	132	17 (12.9)	7.7-19.8	32 (24.2)	17.2-32.5	25	128	7 (5.5)	2.2-10.9	29 (22.7)	15.7-30.9